Use of intravenous valproate in a patient with neuroleptic malignant syndrome [4]

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 18, Issue 1, 2006, Pages 131-132

  Tadke, Rahul R ^a   Suryavanshi, Praveen ^a  

^a Panjab Rao Deshmukh Medical College   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; VALPROIC ACID;

ADULT; AUTONOMIC DYSFUNCTION; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG BLOOD LEVEL; FEMALE; FEVER; GENERAL CONDITION IMPROVEMENT; HUMAN; INCONTINENCE; LETTER; MANIA; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; ORIENTATION; PRIORITY JOURNAL; SYMPTOM; TREMOR;

EID: 33244479009     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.18.1.131     Document Type: Letter

References (4)

1. Kruger S, Braunig P: Intravenous valproic acid in the treatment of severe catatonia J Neuropsychiatry Clin Neurosci. 2001; 13(2):303-304
2. Lauterbach EC: Valproate for catatonia: need for caution in patients on SSRIs and antipsychotics.: J Neuropsychiatry Clin Neurosci. 2002; 14(1):84-86
3. Spehlmann R, Norcross K, Rasmus SC, et al: Improvement of stiff-man syndrome with sodium valproate. Neurology. 1981; 31(9):1162-113
4. Grunze H, Erfurth A, Amann B, et al: Intravenous valproate loading in acutely manic and depressed bipolar I patients. J Clin Psychopharmacol 1999; 19(4):303-309